Biomedical Catalyst – Development of a Kv3 Positive Modulator for the treatment of Schizophrenia

生物医学催化剂 — 开发用于治疗精神分裂症的 Kv3 正调节剂

• 批准号: MC_PC_13035
• 负责人: Stephen Williams
• 金额: $ 87.3万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_13035
• 关键词: Biomedical; Catalyst; Development; Kv3; Positive

The Autifony-Newcastle-Manchester consortium will develop a new treatment for schizophrenia that targets a novel brain potassium channel, Kv3, that is intimately linked to the emerging understanding of the pathology of the disorder. This first-in-class treatment has the potential to address significant unmet patient need for schizophrenia, a serious psychiatric illness that has seen diminishing investment in research in recent years, despite the huge social and economic burden that it imposes in the UK and across the world. Patients with schizophrenia have a poor quality of life and poor prognosis due to debilitating cognitive and negative symptoms that make work and relationships difficult to sustain. This new drug will treat these symptoms, providing significant improvement over existing medicines and with a lower burden of side effects. Autifony's drug development will be backed up by three leading UK academic groups in the field.

Autifony-纽卡斯尔-曼彻斯特联盟将开发一种针对精神分裂症的新疗法，该疗法针对一种新型脑钾通道 Kv3，该通道与对该疾病病理学的新兴认识密切相关。这种一流的治疗方法有可能解决精神分裂症患者未满足的巨大需求。精神分裂症是一种严重的精神疾病，尽管它给英国和世界各地带来了巨大的社会和经济负担，但近年来研究投资却在减少。精神分裂症患者的生活质量差，预后差，因为认知衰弱和阴性症状使工作和人际关系难以维持。这种新药将治疗这些症状，与现有药物相比有显着改善，并且副作用负担较低。 Autifony 的药物开发将得到该领域三个领先的英国学术团体的支持。

项目成果

P.2.025 A novel KV3 ion channel modulator restores cognitive function in an animal model of cognitive impairment in schizophrenia

P.2.025 一种新型 KV3 离子通道调节剂可恢复精神分裂症认知障碍动物模型的认知功能

• DOI: 10.1016/s0924-977x(14)70056-2
• 发表时间: 2014
• 期刊: European Neuropsychopharmacology
• 影响因子: 5.6
• 作者: Leger M